AzaSite®

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Blepharitis

Conditions

Blepharitis

Trial Timeline

Apr 1, 2008 → —

NCT ID

NCT00656539

About AzaSite®

AzaSite® is a approved stage product being developed by Merck for Blepharitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00656539. Target conditions include Blepharitis.

What happened to similar drugs?

4 of 9 similar drugs in Blepharitis were approved

Approved (4) Terminated (1) Active (4)

✅Lotilaner ophthalmic solution, 0.25% + Vehicle controlTarsus PharmaceuticalsApproved

✅AzaSite®MerckApproved

🔄TP-03 + TP-03 VehicleTarsus PharmaceuticalsPhase 3

🔄Lotilaner + Vehicle ControlLianBioPhase 3

🔄ISV-305Sun PharmaceuticalPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00656539	Approved	Completed	Apr 1, 2008	—	Blepharitis
NCT00629941	Approved	Completed	Mar 1, 2008	—	Blepharitis
NCT00629590	Approved	Completed	Mar 1, 2008	—	Blepharitis
NCT00629980	Approved	Completed	Feb 1, 2008	—	Blepharitis

Competing Products

15 competing products in Blepharitis

See all competitors

Product	Company	Stage	Hype Score
Lotilaner ophthalmic solution, 0.25% + Vehicle control	Tarsus Pharmaceuticals	Approved	37
TP-03 + TP-03 Vehicle	Tarsus Pharmaceuticals	Phase 3	34
TP-03, 0.25% + TP-03 Vehicle	Tarsus Pharmaceuticals	Phase 2/3	32
Lotilaner + Vehicle Control	LianBio	Phase 3	30
ISV-305	Sun Pharmaceutical	Phase 3	40
ISV-502 (1.0% azithromycin and 0.1% dexamethasone combined) + Azasite + Dexamethasone	Sun Pharmaceutical	Phase 3	40
AzaSite®	Merck	Approved	43
AzaSite®	Merck	Approved	43
Azithromycin ophthalmic solution, 1% + Placebo	Merck	Phase 2	35
AzaSite®	Merck	Approved	43
Azithromycin ophthalmic solution, 1% + Placebo	Merck	Phase 2	35
Azithromycin ophthalmic solution, 1% + Vehicle	Merck	Phase 2	27
Pimecrolimus 0.3% Ophthalmic Ointment + Placebo Ophthalmic Ointment	Viatris	Phase 3	29
GLK-321 low dose BID + GLK-321 mid dose BID + GLK-321 high dose BID + GLK-321 high dose QD + Placebo BID	Glaukos	Phase 2	39
KPI-121 + Vehicle	Kala Pharmaceuticals	Phase 2	25